Docality.com Logo
 
Dr. Richard  Fishbein  Md image

Dr. Richard Fishbein Md

102 East High Street
Manchester TN 37355
931 237-7066
Medical School: New York University School Of Medicine - 1965
Accepts Medicare: Yes
Participates In eRX: No
Participates In PQRS: No
Participates In EHR: No
License #: MD013323
NPI: 1982761441
Taxonomy Codes:
207X00000X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Richard Fishbein is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:99213 Description:Office/outpatient visit est Average Price:$175.00 Average Price Allowed
By Medicare:
$65.75
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$195.00 Average Price Allowed
By Medicare:
$97.46

HCPCS Code Definitions

99213
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1497842520
Diagnostic Radiology
431
1316974637
Cardiovascular Disease (Cardiology)
388
1033191986
Diagnostic Radiology
270
1417900812
Emergency Medicine
162
*These referrals represent the top 10 that Dr. Fishbein has made to other doctors

Publications

Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry. - Pediatric pulmonology
The objective of the Registry was to characterize the population of infants receiving prophylaxis for respiratory syncytial virus (RSV) disease by describing the patterns and scope of usage of palivizumab in a cross section of US infants. RSV hospitalization outcomes were also described. The Palivizumab (Synagis, MedImmune, Inc., 25 West Watkins Mill Road, Gaithersburg, MD 20878) Outcomes Registry was a prospective multicenter survey conducted at 63 sites. Demographics, injection history, and RSV hospitalization outcomes were collected on 2,116 infants receiving palivizumab. Infants were enrolled in the Registry between September 1, 2000-March 1, 2001, at the time of their first injection. Infants born at less than 32 weeks of gestation accounted for 47% of infants enrolled, and those between 32-35 weeks accounted for 45%; approximately 8% were greater than 35 weeks of gestation. Lower RSV hospitalization rates were observed in infants who had greater adherence to regularly scheduled injections. Nearly one-half of all hospitalizations occurred within the first and second injection intervals, suggesting the importance of early RSV protection. The confirmed RSV hospitalization rate of all infants in the Registry was 2.9%; the rate was 5.8% in infants with chronic lung disease of infancy, and 2.1% in premature infants without chronic lung disease. In conclusion, these data support the continued effectiveness of palivizumab prophylaxis for severe RSV lower respiratory tract disease in a large cohort of high-risk infants from geographically diverse pediatric offices and clinics. The Palivizumab Outcomes Registry provides an opportunity to assess palivizumab utilization and clinical effectiveness in the US.Copyright 2003 Wiley-Liss, Inc.

Map & Directions

102 East High Street Manchester, TN 37355
View Directions In Google Maps

Nearby Doctors

1240 Mcarthur St
Manchester, TN 37355
931 283-3501
1655 Hillsboro Blvd
Manchester, TN 37355
931 289-9791
1642 Mcarthur St
Manchester, TN 37355
931 281-1315
1425 Mcarthur St
Manchester, TN 37355
931 280-0469
2518 Hillsboro Blvd
Manchester, TN 37355
931 238-8882
905 Mcarthur St
Manchester, TN 37355
931 280-0155
1240 Mcarthur St
Manchester, TN 37355
931 283-3501
2345 Murfreesboro Hwy
Manchester, TN 37355
931 285-5607
822 Mcarthur St
Manchester, TN 37355
931 237-7121
1425 Mcarthur St
Manchester, TN 37355
931 280-0469